Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting metabolic syndrome.

Tung M Fong1

  • 1Department of Metabolic Disorders, R80M-213, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. tung_fong@merck.com

Expert Opinion on Investigational Drugs
|August 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.

JAMA ophthalmology·2023
Same author

Constitutive activity in cannabinoid receptors.

Advances in pharmacology (San Diego, Calif.)·2014
Same author

Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.

Metabolism: clinical and experimental·2011
Same author

Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.

Bioorganic & medicinal chemistry letters·2011
Same author

MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice.

Behavioural pharmacology·2011
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Metabolic syndrome, a cluster of risk factors including obesity and diabetes, requires better treatments. Research is exploring new molecular targets for effective intervention and prevention strategies.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Disease Research

Background:

  • Metabolic syndrome is a cluster of cardiovascular disease risk factors: obesity, diabetes, dyslipidemia, and hypertension.
  • Current treatments address individual components, but a comprehensive agent for metabolic syndrome is lacking.

Framework:

  • A 2004 meeting, 'Targeting Metabolic Syndrome,' convened experts to discuss clinical definitions and pathophysiology.
  • Focus on consensus criteria for metabolic syndrome diagnosis.

Implementation:

  • Exploration of potential molecular targets for pharmacological intervention.
  • Review of promising drug discovery efforts targeting central nervous system and peripheral mechanisms.

Implications:

  • Effective control of obesity and insulin resistance is key for metabolic syndrome prevention and treatment.

Related Experiment Videos

  • Development of new regulatory guidelines is necessary for emerging treatment options.
  • Modulating identified molecular targets may treat multiple metabolic syndrome components.